PURPOSE: Most neuroblastomas initially respond to therapy but many relapse with chemoresistant disease. p53 mutations are rare in diagnostic neuroblastomas, but we have previously reported inactivation of the p53/MDM2/p14(ARF) pathway in 9 of 17 (53%) neuroblastoma cell lines established at relapse. HYPOTHESIS: Inactivation of the p53/MDM2/p14(ARF) pathway develops during treatment and contributes to neuroblastoma relapse. METHODS: Eighty-four neuroblastomas were studied from 41 patients with relapsed neuroblastoma including 38 paired neuroblastomas at different stages of therapy. p53 mutations were detected by automated sequencing, p14(ARF) methylation and deletion by methylation-specific PCR and duplex PCR, respectively, and MDM2 amplification by fluorescent in situ hybridization. RESULTS: Abnormalities in the p53 pathway were identified in 20 of 41 (49%) cases. Downstream defects due to inactivating missense p53 mutations were identified in 6 of 41 (15%) cases, 5 following chemotherapy and/or at relapse and 1 at diagnosis, postchemotherapy, and relapse. The presence of a p53 mutation was independently prognostic for overall survival (hazard ratio, 3.4; 95% confidence interval, 1.2-9.9; P = 0.02). Upstream defects were present in 35% of cases: MDM2 amplification in 3 cases, all at diagnosis and relapse and p14(ARF) inactivation in 12 of 41 (29%) cases: 3 had p14(ARF) methylation, 2 after chemotherapy, and 9 had homozygous deletions, 8 at diagnosis and relapse. CONCLUSIONS: These results show that a high proportion of neuroblastomas which relapse have an abnormality in the p53 pathway. The majority have upstream defects suggesting that agents which reactivate wild-type p53 would be beneficial, in contrast to those with downstream defects in which p53-independent therapies are indicated.
PURPOSE: Most neuroblastomas initially respond to therapy but many relapse with chemoresistant disease. p53 mutations are rare in diagnostic neuroblastomas, but we have previously reported inactivation of the p53/MDM2/p14(ARF) pathway in 9 of 17 (53%) neuroblastoma cell lines established at relapse. HYPOTHESIS: Inactivation of the p53/MDM2/p14(ARF) pathway develops during treatment and contributes to neuroblastoma relapse. METHODS: Eighty-four neuroblastomas were studied from 41 patients with relapsed neuroblastoma including 38 paired neuroblastomas at different stages of therapy. p53 mutations were detected by automated sequencing, p14(ARF) methylation and deletion by methylation-specific PCR and duplex PCR, respectively, and MDM2 amplification by fluorescent in situ hybridization. RESULTS: Abnormalities in the p53 pathway were identified in 20 of 41 (49%) cases. Downstream defects due to inactivating missense p53 mutations were identified in 6 of 41 (15%) cases, 5 following chemotherapy and/or at relapse and 1 at diagnosis, postchemotherapy, and relapse. The presence of a p53 mutation was independently prognostic for overall survival (hazard ratio, 3.4; 95% confidence interval, 1.2-9.9; P = 0.02). Upstream defects were present in 35% of cases: MDM2 amplification in 3 cases, all at diagnosis and relapse and p14(ARF) inactivation in 12 of 41 (29%) cases: 3 had p14(ARF) methylation, 2 after chemotherapy, and 9 had homozygous deletions, 8 at diagnosis and relapse. CONCLUSIONS: These results show that a high proportion of neuroblastomas which relapse have an abnormality in the p53 pathway. The majority have upstream defects suggesting that agents which reactivate wild-type p53 would be beneficial, in contrast to those with downstream defects in which p53-independent therapies are indicated.
Authors: N K Cheung; B H Kushner; M LaQuaglia; K Kramer; S Gollamudi; G Heller; W Gerald; S Yeh; R Finn; S M Larson; D Wuest; M Byrnes; E Dantis; J Mora; I Y Cheung; N Rosenfield; S Abramson; R J O'Reilly Journal: Med Pediatr Oncol Date: 2001-01
Authors: N Keshelava; J J Zuo; P Chen; S N Waidyaratne; M C Luna; C J Gomer; T J Triche; C P Reynolds Journal: Cancer Res Date: 2001-08-15 Impact factor: 12.701
Authors: Annemieke de Vries; Elsa R Flores; Barbara Miranda; Harn-Mei Hsieh; Conny Th M van Oostrom; Julien Sage; Tyler Jacks Journal: Proc Natl Acad Sci U S A Date: 2002-02-26 Impact factor: 11.205
Authors: M Omura-Minamisawa; M B Diccianni; R C Chang; A Batova; L J Bridgeman; J Schiff; S L Cohn; W B London; A L Yu Journal: Clin Cancer Res Date: 2001-11 Impact factor: 12.531
Authors: I M Ambros; J Benard; M Boavida; N Bown; H Caron; V Combaret; J Couturier; C Darnfors; O Delattre; J Freeman-Edward; C Gambini; N Gross; C M Hattinger; A Luegmayr; J Lunec; T Martinsson; K Mazzocco; S Navarro; R Noguera; S O'Neill; U Potschger; S Rumpler; F Speleman; G P Tonini; A Valent; N Van Roy; G Amann; B De Bernardi; P Kogner; R Ladenstein; J Michon; A D J Pearson; P F Ambros Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: Kristina A Cole; Jonathan Huggins; Michael Laquaglia; Chase E Hulderman; Mike R Russell; Kristopher Bosse; Sharon J Diskin; Edward F Attiyeh; Rachel Sennett; Geoffrey Norris; Marci Laudenslager; Andrew C Wood; Patrick A Mayes; Jayanti Jagannathan; Cynthia Winter; Yael P Mosse; John M Maris Journal: Proc Natl Acad Sci U S A Date: 2011-02-02 Impact factor: 11.205
Authors: Lucas Moreno; Andrew D J Pearson; Xavier Paoletti; Irene Jimenez; Birgit Geoerger; Pamela R Kearns; C Michel Zwaan; Francois Doz; Andre Baruchel; Josef Vormoor; Michela Casanova; Stefan M Pfister; Bruce Morland; Gilles Vassal Journal: Nat Rev Clin Oncol Date: 2017-05-16 Impact factor: 66.675
Authors: Kateryna Krytska; Hannah T Ryles; Renata Sano; Pichai Raman; Nicole R Infarinato; Theodore D Hansel; Monish R Makena; Michael M Song; C Patrick Reynolds; Yael P Mossé Journal: Clin Cancer Res Date: 2015-10-05 Impact factor: 12.531
Authors: Myrthala Moreno-Smith; Anna Lakoma; Zaowen Chen; Ling Tao; Kathleen A Scorsone; Linda Schild; Kevin Aviles-Padilla; Rana Nikzad; Yankai Zhang; Rikhia Chakraborty; Jan J Molenaar; Sanjeev A Vasudevan; Vivien Sheehan; Eugene S Kim; Silke Paust; Jason M Shohet; Eveline Barbieri Journal: Clin Cancer Res Date: 2017-08-18 Impact factor: 12.531